Various tyrosine kinase inhibitors, in particular, have shown high response rates (58–85 %) in brain metastases among EGFR mutation-positive non-small cell lung cancer patients, in whom brain metastases are common (Iuchi and Hara, 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.